Investors
OMX Stockholm
Some content on this page is only available in English. All material required under applicable law, regulation or code is available in English and Swedish.
Upcoming events
Pareto Securities’ 16th Annual Healthcare Conference 2025
Interim Report for January-September 2025
SEB Healthcare Conference, Stockholm
Press releases
Our latest press releases
Regulatory press release
17/07/2025
08/07/2025
03/07/2025
30/06/2025
Hansa Biopharma in brief
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions.
Key progress and look ahead
Desensitization: Transplantation and Gene Therapy
Phase 3 Top Line Data Readout: pivotal US trial in kidney transplantation (ConfIdeS)
Phase 1b Initial Data Readout: global trial in Duchenne Muscular Dystrophy with Sarepta (SRP-9001-104)
Phase 2 Top Line Data Readout: global trial in Crigler Najjar with Genethon (GNT-018-IDES)
Autoimmune Disease
Phase 3 Top Line Data Readout: global trial in anti-GBM (GOOD-IDES-02)
Phase 2 Data Publication: single arm trial in GBS (15-HMedIdeS-09)
